Reteplase is a purified form of human tissue plasminogen activator used in the emergency treatment of myocardial infarction, ischemic stroke, and pulmonary emboli. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA.
- Mechanism
- Curator reviewed
Reteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action.
- Primary indication
- For lysis of acute pulmonary emboli, intracoronary emboli, and management of myocardial infarction.Curator reviewed · 3 structured indications
- Formula / weight
- C1736H2671N499O522S22 · 39589.6 Da
- First approval
- Canada, 2008 · United States, 1996
- Also known as
- Human t-PA (residues 1-3 and 176-527) · Reteplase, recombinant · Reteplase,recombinant
- Code names
- BM-06.022
Resolves to
What you can answer from here — as of July 17, 2026
Which drugs share a target with Reteplase, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account